Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Pediatric Radiology
Published in: Pediatric Radiology 12/2022

10-05-2022 | Rickets | Review

Disorders of phosphate homeostasis in children, part 1: primer on mineral ion homeostasis and the roles of phosphate in skeletal biology

Author: Richard M. Shore

Published in: Pediatric Radiology | Issue 12/2022

Login to get access

Abstract

Phosphate has extensive physiological roles including energy metabolism, genetic function, signal transduction and membrane integrity. Regarding the skeleton, not only do phosphate and calcium form the mineral component of the skeleton, but phosphate is also essential in regulating function of skeletal cells. Although our understanding of phosphate homeostasis has lagged behind and remains less than that for calcium, considerable advances have been made since the recognition of fibroblast growth factor-23 (FGF23) as a bone-derived phosphaturic hormone that is a major regulator of phosphate homeostasis. In this two-part review of disorders of phosphate homeostasis in children, part 1 covers the basics of mineral ion homeostasis and the roles of phosphate in skeletal biology. Part 1 includes phosphate-related disorders of mineralization for which overall circulating mineral ion homeostasis remains normal. Part 2 covers hypophosphatemic and hyperphosphatemic disorders, emphasizing, but not limited to, those related to increased and decreased FGF23 signaling, respectively.
Literature
1.
Christov M, Jüppner H (2018) Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab 32:685–706PubMedCrossRef
2.
Kinoshita Y, Fukumoto S (2018) X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment. Endocr Rev 39:274–291PubMedCrossRef
3.
Bitzan M, Goodyer PR (2019) Hypophosphatemic rickets. Pediatr Clin N Am 66:179–207CrossRef
4.
Meyer RA, Meyer MH, Gray RW (1989) Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 4:493–500PubMedCrossRef
5.
Levine BS, Kleeman CR, Felsenfeld AJ (2009) The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport. Clin J Am Soc Nephrol 4:1866–1877PubMedCrossRef
6.
ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef
7.
8.
Shimada T, Mizutani S, Muto T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500–6505PubMedPubMedCentralCrossRef
9.
Jan de Beur SM, Levine MA (2002) Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 87:2467–2473PubMedCrossRef
10.
Balani S, Perwad F (2019) Fibroblast growth factor 23 and phosphate homeostasis. Curr Opin Nephrol Hypertens 28:465–473PubMedCrossRef
11.
Bar L, Stournaras C, Lang F et al (2019) Regulation of fibroblast growth factor 23 (FGF23) in health and disease. FEBS Lett 593:1879–1900PubMedCrossRef
12.
Vervloet M (2019) Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol 15:109–120PubMedCrossRef
13.
Bacchetta J, Bardet C, Prié D (2020) Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. Metabolism 103s:153865PubMedCrossRef
14.
Takashi Y, Fukumoto S (2020) Phosphate-sensing and regulatory mechanism of FGF23 production. J Endocrinol Investig 43:877–883CrossRef
15.
Figueres L, Beck-Cormier S, Beck L, Marks J (2021) The complexities of organ crosstalk in phosphate homeostasis: time to put phosphate sensing back in the limelight. Int J Mol Sci 22:5701PubMedPubMedCentralCrossRef
16.
Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401PubMedCrossRef
17.
18.
Orriss IR, Arnett TR, Russell RG (2016) Pyrophosphate: a key inhibitor of mineralisation. Curr Opin Pharmacol 28:57–68PubMedCrossRef
19.
Cui L, Houston DA, Farquharson C, MacRae VE (2016) Characterisation of matrix vesicles in skeletal and soft tissue mineralisation. Bone 87:147–158PubMedCrossRef
20.
Anderson HC, Garimella R, Tague SE (2005) The role of matrix vesicles in growth plate development and biomineralization. Front Biosci 10:822–837PubMedCrossRef
21.
Millán JL (2013) The role of phosphatases in the initiation of skeletal mineralization. Calcif Tissue Int 93:299–306PubMedCrossRef
22.
Bottini M, Mebarek S, Anderson KL et al (2018) Matrix vesicles from chondrocytes and osteoblasts: their biogenesis, properties, functions and biomimetic models. Biochim Biophys Acta Gen Subj 1862:532–546PubMedCrossRef
23.
Kimata M, Michigami T, Tachikawa K et al (2010) Signaling of extracellular inorganic phosphate up-regulates cyclin D1 expression in proliferating chondrocytes via the Na+/pi cotransporter pit-1 and Raf/MEK/ERK pathway. Bone 47:938–947PubMedCrossRef
24.
Michigami T, Ozono K (2019) Roles of phosphate in skeleton. Front Endocrinol 10:180CrossRef
25.
Millán JL, Whyte MP (2016) Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int 98:398–416PubMedCrossRef
26.
27.
Montaner Ramón A (2020) Risk factors of bone mineral metabolic disorders. Semin Fetal Neonatal Med 25:101068PubMedCrossRef
28.
Chinoy A, Mughal MZ, Padidela R (2019) Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences. Arch Dis Child Fetal Neonatal Ed 104:F560–f566PubMedCrossRef
29.
Schulz EV, Wagner CL (2020) History, epidemiology and prevalence of neonatal bone mineral metabolic disorders. Semin Fetal Neonatal Med 25:101069PubMedCrossRef
30.
31.
32.
Done SL (2012) Fetal and neonatal bone health: update on bone growth and manifestations in health and disease. Pediatr Radiol 42:S158–S176PubMedCrossRef
33.
Viswanathan S, Khasawneh W, McNelis K et al (2014) Metabolic bone disease: a continued challenge in extremely low birth weight infants. JPEN J Parenter Enteral Nutr 38:982–990PubMedCrossRef
34.
Harrison CM, Gibson AT (2013) Osteopenia in preterm infants. Arch Dis Child Fetal Neonatal Ed 98:F272–F275PubMedCrossRef
35.
Mornet E (2018) Hypophosphatasia. Metabolism 82:142–155
36.
Fauvert D, Brun-Heath I, Lia-Baldini AS et al (2009) Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. BMC Med Genet 10:51PubMedPubMedCentralCrossRef
37.
Lia-Baldini AS, Brun-Heath I, Carrion C et al (2008) A new mechanism of dominance in hypophosphatasia: the mutated protein can disturb the cell localization of the wild-type protein. Hum Genet 123:429–432PubMedCrossRef
38.
Lia-Baldini AS, Muller F, Taillandier A et al (2001) A molecular approach to dominance in hypophosphatasia. Hum Genet 109:99–108PubMedCrossRef
39.
Ornoy A, Adomian GE, Rimoin DL (1985) Histologic and ultrastructural studies on the mineralization process in hypophosphatasia. Am J Med Genet 22:743–758PubMedCrossRef
40.
Shohat M, Rimoin DL, Gruber HE, Lachman RS (1991) Perinatal lethal hypophosphatasia; [sic] clinical, radiologic and morphologic findings. Pediatr Radiol 21:421–427PubMedCrossRef
41.
Zhang Z, Nam HK, Crouch S, Hatch NE (2021) Tissue nonspecific alkaline phosphatase function in bone and muscle progenitor cells: control of mitochondrial respiration and ATP production. Int J Mol Sci 22:1140PubMedPubMedCentralCrossRef
42.
Khan AA, Josse R, Kannu P et al (2019) Hypophosphatasia: Canadian update on diagnosis and management. Osteoporos Int 30:1713–1722PubMedCrossRef
43.
Whyte MP, Zhang F, Wenkert D et al (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone 75:229–239PubMedCrossRef
44.
45.
46.
Kozlowski K, Sutcliffe J, Barylak A et al (1976) Hypophosphatasia. Review of 24 cases. Pediatr Radiol 5:103–117PubMedCrossRef
47.
Shore RM (2008) Metabolic bone disease. In: Slovis TL (ed) Caffey's pediatric diagnostic imaging, 11th edn. Elsevier, Philadelphia, pp 2726–2752CrossRef
48.
Wenkert D, McAlister WH, Coburn SP et al (2011) Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res 26:2389–2398PubMedCrossRef
49.
Whyte MP, Greenberg CR, Salman NJ et al (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904–913PubMedCrossRef
50.
Whyte MP (2017) Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res 32:667–675PubMedCrossRef
51.
52.
Boyce AM, Gafni RI, Ferreira CR (2020) Generalized arterial calcification of infancy: new insights, controversies, and approach to management. Curr Osteoporos Rep 18:232–241PubMedPubMedCentralCrossRef
53.
Nitschke Y, Yan Y, Buers I et al (2018) ENPP1-fc prevents neointima formation in generalized arterial calcification of infancy through the generation of AMP. Exp Mol Med 50:1–12PubMedCrossRef
54.
Ferreira CR, Hackbarth ME, Ziegler SG et al (2021) Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet Med 23:396–407PubMedCrossRef
55.
Chong CR, Hutchins GM (2008) Idiopathic infantile arterial calcification: the spectrum of clinical presentations. Pediatr Dev Pathol 11:405–415PubMedCrossRef
56.
Ferreira CR, Kintzinger K, Hackbarth ME et al (2021) Ectopic calcification and hypophosphatemic rickets: natural history of ENPP1 and ABCC6 deficiencies. J Bone Miner Res 36:2193–2202PubMedCrossRef
57.
Hajjawi MO, MacRae VE, Huesa C et al (2014) Mineralisation of collagen rich soft tissues and osteocyte lacunae in Enpp1(−/−) mice. Bone 69:139–147PubMedPubMedCentralCrossRef
Metadata
Title
Disorders of phosphate homeostasis in children, part 1: primer on mineral ion homeostasis and the roles of phosphate in skeletal biology
Author
Richard M. Shore
Publication date
10-05-2022
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Radiology / Issue 12/2022
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-022-05374-y

Other articles of this Issue 12/2022

Pediatric Radiology 12/2022 Go to the issue

Letter to the Editor

Re: ‘Ultrasound for malrotation and volvulus — point’ and ‘Sonographic diagnosis of malrotation: it’s complicated — counterpoint’

Original Article

Whole-body MRI at initial presentation of pediatric chronic recurrent multifocal osteomyelitis and correlation with clinical assessment

Original Article

Pancreatic shear wave elastography in children with type 1 diabetes: relation to diabetes duration, glycemic indices, fasting C-peptide and diabetic complications

Original Article

Quantitative cardiopulmonary magnetic resonance imaging in neonatal congenital diaphragmatic hernia

Editorial

Editors’ notebook: what is ‘pediatric’?

Review

Imaging of pre- and post-cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pediatric intraperitoneal malignancy